Literature DB >> 8865005

Quality of life in brain tumor patients.

A R Giovagnoli1, M Tamburini, A Boiardi.   

Abstract

With the aim of evaluating the quality of life (QL) of 101 brain tumor patients, a multidimensional approach was adopted, using the Functional Living Index-Cancer (FLIC) as a global measure of well-being, the Karnofsky Performance Scale (KPS) and the Index of Independence in Activity of Daily Living (ADL) as indices of physical and functional dimensions, the State-Trait Anxiety Inventory (STAI) and the Self-Rating Depression Scale (SRDS) for psychological assessment, and neuropsychological tests for abstract reasoning, attention, memory and frontal lobe functions. The patients were grouped on the grounds of disease stage and treatment. The FLIC and KPS ratings increased from the patients who had just undergone surgery to patients who were disease-free after completing chemotherapy and radiotherapy, thus showing that the QL may improve during the disease despite aggressive treatments, providing there is no tumor recurrence. However, only the FLIC consistently discriminated the patients' stratification. The ADL revealed no between-group differences, whereas the STAI and SRDS revealed the presence of emotional troubles at the beginning and at the end of treatment. Cognitive impairment was more serious after radiotherapy and chemotherapy, as well as in patients with tumor recurrence. The FLIC significantly correlated with all of the other scales used, showing that it is useful in summarizing both the physical and psychosocial impairment of brain tumor patients. Of the pathological variables, a tumor location in the anterior right hemisphere or diencephalon was associated with high FLIC ratings, may be due to the minor cognitive impairment observed in patients with these tumor sites. Of the demographic variables, the level of education was associated with high FLIC ratings, thus highlighting the role of psychosocial environment in improving the QL. The use of a multidimensional approach or a global index of well-being that also reflects psychosocial and cognitive aspects proved to be more appropriate than traditional functional instruments (such as the KPS) in assessing the QL of brain tumor patients and in detecting the extent of the disease.

Entities:  

Mesh:

Year:  1996        PMID: 8865005     DOI: 10.1007/bf00177445

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  28 in total

1.  Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas.

Authors:  M Ammirati; N Vick; Y L Liao; I Ciric; M Mikhael
Journal:  Neurosurgery       Date:  1987-08       Impact factor: 4.654

2.  Raven's coloured progressive matrices: normative values on 305 adult normal controls.

Authors:  A Basso; E Capitani; M Laiacona
Journal:  Funct Neurol       Date:  1987 Apr-Jun

3.  A cross-cultural survey of symptoms in depression.

Authors:  W W Zung
Journal:  Am J Psychiatry       Date:  1969-07       Impact factor: 18.112

4.  Long term survival among patients with malignant brain tumors.

Authors:  A N Lieberman; S H Foo; J Ransohoff; A Wise; A George; W Gordon; R Walker
Journal:  Neurosurgery       Date:  1982-04       Impact factor: 4.654

5.  Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.

Authors:  H Schipper; J Clinch; A McMurray; M Levitt
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

6.  Effect of age and reoperation on survival in the combined modality treatment of malignant astrocytoma.

Authors:  M Salcman; R S Kaplan; T B Ducker; H Abdo; E Montgomery
Journal:  Neurosurgery       Date:  1982-04       Impact factor: 4.654

7.  Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores.

Authors:  N Mackworth; P Fobair; M D Prados
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

8.  Cognitive impairment and quality of life in long-term survivors of malignant brain tumors.

Authors:  A R Giovagnoli; A Boiardi
Journal:  Ital J Neurol Sci       Date:  1994-12

9.  Late effects of radiotherapy on patients with cerebellar medulloblastoma.

Authors:  C L Silverman; H Palkes; B Talent; E Kovnar; J W Clouse; P R Thomas
Journal:  Cancer       Date:  1984-09-01       Impact factor: 6.860

10.  Neuropsychological assessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy.

Authors:  J R Crossen; D L Goldman; S A Dahlborg; E A Neuwelt
Journal:  Neurosurgery       Date:  1992-01       Impact factor: 4.654

View more
  29 in total

1.  Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumour.

Authors:  A R Giovagnoli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Concordance of patient and caregiver reports in evaluating quality of life in patients with malignant gliomas and an assessment of caregiver burden.

Authors:  Daniel I Jacobs; Priya Kumthekar; Becky V Stell; Sean A Grimm; Alfred W Rademaker; Laurie Rice; James P Chandler; Kenji Muro; MaryAnne Marymont; Irene B Helenowski; Lynne I Wagner; Jeffrey J Raizer
Journal:  Neurooncol Pract       Date:  2014-05-05

3.  Recurrent brain tumour: the impact of illness on patient's life.

Authors:  Elena Lamperti; Giuseppe Pantaleo; Claudia Yvonne Finocchiaro; Antonio Silvani; Andrea Botturi; Paola Gaviani; Lucio Sarno; Andrea Salmaggi
Journal:  Support Care Cancer       Date:  2011-07-03       Impact factor: 3.603

4.  Quantitative measurement of quality outcome in malignant glioma patients using an independent living score (ILS). Assessment of a retrospective cohort.

Authors:  L Recht; M Glantz; M Chamberlain; C C Hsieh
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

5.  Cognitive strategies and quality of life of patients with high-grade glioma.

Authors:  C Lucchiari; A Botturi; A Silvani; E Lamperti; P Gaviani; A Innocenti; C Y Finocchiaro; M Masiero; G Pravettoni
Journal:  Support Care Cancer       Date:  2015-03-12       Impact factor: 3.603

6.  Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues.

Authors:  Guy Pelletier; Marja J Verhoef; Nasreen Khatri; Neil Hagen
Journal:  J Neurooncol       Date:  2002-03       Impact factor: 4.130

7.  Prediction of neurocognitive outcome in adult brain tumor patients.

Authors:  Thomas A Kaleita; David K Wellisch; Timothy F Cloughesy; Judith M Ford; Donald Freeman; Thomas R Belin; Jeffrey Goldman
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

8.  Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing.

Authors:  Lee W Jones; Rachel-Rose Cohen; Stephanie K Mabe; Miranda J West; Annick Desjardins; James J Vredenburgh; Allan H Friedman; David A Reardon; Emily Waner; Henry S Friedman
Journal:  J Neurooncol       Date:  2009-02-11       Impact factor: 4.130

9.  Psychiatric Profile of Retinal Detachment Surgery under Regional Block.

Authors:  Emad Abboud; Afaf Mansour; Waleed Riad
Journal:  Middle East Afr J Ophthalmol       Date:  2008-01

Review 10.  FACT-MNG: tumor site specific web-based outcome instrument for meningioma patients.

Authors:  D Zlotnick; S N Kalkanis; A Quinones-Hinojosa; K Chung; M E Linskey; R L Jensen; F DeMonte; F G Barker; C A Racine; M S Berger; P M Black; M Cusimano; L N Sekhar; A Parsa; M Aghi; Michael W McDermott
Journal:  J Neurooncol       Date:  2010-09-18       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.